These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 12830003)

  • 1. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
    Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
    Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
    Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
    Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence.
    Alberts DS; Martínez ME; Hess LM; Einspahr JG; Green SB; Bhattacharyya AK; Guillen J; Krutzsch M; Batta AK; Salen G; Fales L; Koonce K; Parish D; Clouser M; Roe D; Lance P;
    J Natl Cancer Inst; 2005 Jun; 97(11):846-53. PubMed ID: 15928305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
    Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
    Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
    Poupon RE; Bonnand AM; Chrétien Y; Poupon R
    Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pretransplantation ursodeoxycholic acid therapy on the outcome of liver transplantation in patients with primary biliary cirrhosis.
    Heathcote EJ; Stone J; Cauch-Dudek K; Poupon R; Chazouilleres O; Lindor KD; Petz J; Dickson ER; Poupon RE
    Liver Transpl Surg; 1999 Jul; 5(4):269-74. PubMed ID: 10388499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis.
    Bonnand AM; Heathcote EJ; Lindor KD; Poupon RE
    Hepatology; 1999 Jan; 29(1):39-43. PubMed ID: 9862847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
    Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
    Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
    Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of pruritus in primary biliary cirrhosis.
    Talwalkar JA; Souto E; Jorgensen RA; Lindor KD
    Clin Gastroenterol Hepatol; 2003 Jul; 1(4):297-302. PubMed ID: 15017671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients.
    ter Borg PC; Schalm SW; Hansen BE; van Buuren HR;
    Am J Gastroenterol; 2006 Sep; 101(9):2044-50. PubMed ID: 16848809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of ursodeoxycholic acid on hepatic inflammation and histological stage in patients with primary biliary cirrhosis.
    Batts KP; Jorgensen RA; Dickson ER; Lindor KD
    Am J Gastroenterol; 1996 Nov; 91(11):2314-7. PubMed ID: 8931409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
    Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
    Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
    Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
    Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term ursodeoxycholic acid therapy is associated with reduced risk of biliary pain and acute cholecystitis in patients with gallbladder stones: a cohort analysis.
    Tomida S; Abei M; Yamaguchi T; Matsuzaki Y; Shoda J; Tanaka N; Osuga T
    Hepatology; 1999 Jul; 30(1):6-13. PubMed ID: 10385632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial.
    Papatheodoridis GV; Hadziyannis ES; Deutsch M; Hadziyannis SJ
    Am J Gastroenterol; 2002 Aug; 97(8):2063-70. PubMed ID: 12190178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.
    Hazzan R; Tur-Kaspa R
    J Clin Gastroenterol; 2010; 44(5):371-3. PubMed ID: 19881358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
    Angulo P; Patel T; Jorgensen RA; Therneau TM; Lindor KD
    Hepatology; 2000 Nov; 32(5):897-900. PubMed ID: 11050036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
    J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.